Over the past two decades, polymer-based drug delivery systems have evolved from experimental concepts to clinically validated technologies, playing a key role in the development of next-generation therapeutics.
At Curapath, with over 13 years of hands-on expertise, we support biotech and pharmaceutical companies with polymer and lipid-based solutions, from early development to GMP manufacturing. I
In this article, we explore how advanced polymer technologies are enabling breakthroughs in DNA and RNA delivery, targeted LNPs, polymer–drug conjugates, and medical devices, while overcoming key limitations of conventional approaches such as PEGylation and viral vectors.
Next-Generation Transfection Reagents for DNA Delivery and In Vivo CAR-T
Polymers are emerging as powerful alternatives to viral vectors for DNA delivery, enabling safer and more flexible approaches for DNA vaccines and in vivo CAR-T therapies.
At Curapath, we develop high-performance transfection reagents designed to address key challenges in nucleic acid delivery:
- High transfection efficiency for DNA
- Reduced toxicity compared to conventional systems
- Low immune response, enabling multiple dosing
- Biodegradable profiles, improving safety in vivo
Our portfolio includes:
- STAR polymers: a patented, high-performance targetable transfection reagents for DNA vaccines and in vivo CAR-T
- PSar shielding polymers: a shielding strategy that reduces toxicity when combined with transfection reagents and polycations in vivo
- Nanoparticle stabilizers like PEG-PGA(currently being manufactured for a Phase III Clinical trial): clinically advanced shielding solutions
- Tunable transfection platforms:
- PBAEs
- Modified poly-amino acids (PLys, PLO, PArg)
- PAMAM dendrimers
These systems provide a modular and tunable toolbox for in vivo nucleic acid delivery, enabling optimized performance depending on the therapeutic application.
PEG Alternatives: Overcoming the Limitations of PEGylation
While PEGylation has long been a standard strategy in drug delivery, it presents well-known limitations, including immunogenicity and accelerated blood clearance (ABC effect).
At Curapath, we develop next-generation PEG alternatives designed to improve safety and performance:
- Low immune response and reduced reactogenicity
- Avoidance of anti-PEG antibody formation
- Biodegradability, reducing long-term accumulation
- Lower bioaccumulation vs PEG
- Prevention of accelerated blood clearance, enabling repeat dosing
These materials are critical for advancing RNA therapeutics, biologics, and nanoparticle-based delivery systems.
Advanced Shielding Lipids for LNPs and Targeted RNA Delivery
Polymers play a central role in the design of lipid nanoparticles (LNPs) for:
- mRNA vaccines
- Gene therapy
- Gene editing
- Oncology applications
At Curapath, we offer a broad portfolio of PEG-free shielding lipids and polymers, including:
- PSar (polysarcosine) a versatile, tunable, and targetable platform alredy being tested in clinical trials
- VitE-PSar our patented derivative with enhanced stability in solution
- PGA-diol a patented polymer tehcnology enabling freeze-dried LNP stability, long-term storage, and inhalation delivery
- pBetaines a family of patented zwitterionic shielding lipids
- POx (polyoxazolines) another tunable and highly adaptable platform
These solutions enable stable, scalable, and clinically translatable LNP formulations, while reducing dependence on PEG.
Targeted LNPs Enabled by CliCr® Click Chemistry
For targeted lipid nanoparticles, Curapath goes beyond conventional formulations.
We develop PSar-based polymers with lipid anchors (C14, C16, C18) that enable precise control over nanoparticle surface properties.
Combined with our proprietary CliCr® click-chemistry platform, these systems allow:
- Efficient and scalable ligand conjugation
- High functionalization density
- Preservation of nanoparticle integrity
This enables advanced strategies for:
- Tissue-specific targeting
- Extrahepatic delivery (lung, T cells, CNS, bone marrow)
Polymer-Based Solubilization Solutions for Biologics
Polymers also provide powerful solutions for improving the stability and solubility of biologics, including mAbs, proteins, and peptides.
At Curapath, we offer:
- Oleyl-PSar our patented alternative to polysorbates
- Improved oxidative stability
- Enhanced solubility performance
- Ideal for next-generation biologics formulations
- PSarylation a next-generation polymer–biologic conjugation strategy alternative to PEGylation
- Biodegradable alternative to 40 kDa PEGylation
- Tunable chain length for optimized performance
These technologies are suitable for topical and injectable formulations, supporting more stable and effective biologics.
Polymer–Drug Conjugates
Polymer–drug conjugates are powerful tools for improving the performance of both small molecules and biologics, particularly in:
- Oncology
- Infectious diseases
Key advantages include:
- Improved drug stability and circulation time
- Reduced off-target toxicity (critical for HPAPIs)
- Enhanced tissue and cellular targeting
- Compatibility with small molecules and biologics
Our platforms include:
- PGA (polyglutamic acid) → biodegradable alternative to PEG and HPMA
- PLys, PLO (ornithine), and related copolymers
These systems enable the development of more effective and safer therapeutic candidates.
From DNA delivery and RNA therapeutics to polymer–drug conjugates , polymers are redefining what is possible in modern medicine.
At Curapath, we combine:
- Proven platforms
- Innovative materials
- GMP capabilities
to act as a true development partner, helping our clients accelerate the path from concept to clinic.
